Mesutoclax not checked

Beijing InnoCare Pharma Tech Co., Ltd. · ICP-248

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
8 active
8 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Eligible patients will receive ICP-248 orally as per the protocol”In the company’s words, NCT07896590 on ClinicalTrials.gov
Tested for
Relapsed or Refractory Mantle Cell Lymphoma (MCL) (2 trials), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Acute Myeloblastic Leukemia, Hematologic Malignancies, Hematological Malignancies, Mature B-cell Malignancies, Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Main trialPhase 3
“To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL”In the company’s words, NCT07896590 on ClinicalTrials.gov
Other names
ICP-248

Other drugs for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

All 266 drugs for Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Coming up7

Changes2

Last 90 days

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Oct 2028 Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
Phase 3Recruiting Dec 2029 A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
Phase 3Not yet recruiting Oct 2032 A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
Phase 2/3Recruiting 25 Nov 2030 ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Phase 2Recruiting Dec 2027 A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Phase 1Recruiting 30 Aug 2025 The Study of ICP-248 in Patients With Mature B-cell Malignancies
Phase 1Recruiting 25 Jun 2027 Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Phase 1Recruiting Jun 2027 ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mesutoclax

Following is part of Solo: you see every change to Mesutoclax the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in